NASDAQ:URGN UroGen Pharma (URGN) Stock Price, News & Analysis $15.40 +0.39 (+2.60%) (As of 10:39 AM ET) Add Compare Share Share Today's Range$15.10▼$15.6750-Day Range$12.72▼$19.2052-Week Range$8.69▼$24.13Volume116,379 shsAverage Volume469,034 shsMarket Capitalization$361.19 millionP/E RatioN/ADividend YieldN/APrice Target$51.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get UroGen Pharma alerts: Email Address UroGen Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside240.9% Upside$51.17 Price TargetShort InterestBearish23.96% of Shares Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews Sentiment0.60Based on 8 Articles This WeekInsider TradingSelling Shares$67,401 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.52) to ($2.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.11 out of 5 starsMedical Sector162nd out of 896 stocksPharmaceutical Preparations Industry62nd out of 424 stocks 3.5 Analyst's Opinion Consensus RatingUroGen Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUroGen Pharma has only been the subject of 3 research reports in the past 90 days.Read more about UroGen Pharma's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted23.96% of the outstanding shares of UroGen Pharma have been sold short.Short Interest Ratio / Days to CoverUroGen Pharma has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in UroGen Pharma has recently increased by 6.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldUroGen Pharma does not currently pay a dividend.Dividend GrowthUroGen Pharma does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUroGen Pharma has received a 70.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other cancer medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for UroGen Pharma is -1.33. Previous Next 2.6 News and Social Media Coverage News SentimentUroGen Pharma has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for UroGen Pharma this week, compared to 2 articles on an average week.Search Interest6 people have searched for URGN on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -73% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, UroGen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $67,401.00 in company stock.Percentage Held by Insiders11.13% of the stock of UroGen Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.29% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about UroGen Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for UroGen Pharma are expected to grow in the coming year, from ($3.52) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of UroGen Pharma is -4.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of UroGen Pharma is -4.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about UroGen Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin Analytics50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the start of the year.So why are top hedge funds currently dumping their stocks? About UroGen Pharma Stock (NASDAQ:URGN)UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Read More URGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart URGN Stock News HeadlinesJune 13, 2024 | insidertrades.comMark Schoenberg Sells 5,153 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) StockJuly 4 at 1:30 AM | americanbankingnews.comQ2 2024 EPS Estimates for UroGen Pharma Ltd. Raised by Analyst (NASDAQ:URGN)July 5, 2024 | Behind the Markets (Ad)[BUY ALERT] “This Could Be Worth 28X More than NVIDIA”This firm's stock is currently trading for only $15. But that won't last long. Because even OpenAI founder Sam Altman admits AI "depends" on this firm's work.July 2 at 3:42 AM | americanbankingnews.comUroGen Pharma (NASDAQ:URGN) Earns Buy Rating from HC WainwrightJuly 1, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN)June 17, 2024 | businesswire.comUroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded WarrantsJune 17, 2024 | globenewswire.comUroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsJune 13, 2024 | investors.comUroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer DrugJuly 5, 2024 | Behind the Markets (Ad)[BUY ALERT] “This Could Be Worth 28X More than NVIDIA”This firm's stock is currently trading for only $15. But that won't last long. Because even OpenAI founder Sam Altman admits AI "depends" on this firm's work.June 13, 2024 | businesswire.comUber Advertising Announces Exclusive Partnership with T-Mobile Advertising SolutionsJune 13, 2024 | businesswire.comAscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100June 13, 2024 | businesswire.comUroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBCJune 7, 2024 | businesswire.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2024 | businesswire.comUroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024June 5, 2024 | businesswire.comUroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare ConferenceJune 3, 2024 | businesswire.comUroGen Pharma Appoints David Lin as New Chief Commercial OfficerMay 22, 2024 | businesswire.comUroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation SummitMay 14, 2024 | markets.businessinsider.comUroGen Pharma Holds Steady Amidst Financial Underperformance and Anticipated Study ResultsMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Urogen Pharma as UGN-102 Progresses Towards FDA Approval and Market SuccessMay 14, 2024 | msn.comUroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comUroGen Pharma Ltd (URGN) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...May 14, 2024 | finance.yahoo.comUroGen Pharma First Quarter 2024 Earnings: Misses ExpectationsMay 13, 2024 | investorplace.comURGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024May 13, 2024 | finance.yahoo.comUroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above ExpectationsMay 13, 2024 | businesswire.comUroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business HighlightsMay 12, 2024 | finance.yahoo.comShareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past weekMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Urogen Pharma on Strong Clinical Data and Market PotentialSee More Headlines Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/05/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:URGN CUSIPN/A CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees204Year FoundedN/APrice Target and Rating Average Stock Price Target$51.17 High Stock Price Target$60.00 Low Stock Price Target$40.00 Potential Upside/Downside+240.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,240,000.00 Net Margins-123.74% Pretax Margin-119.05% Return on EquityN/A Return on Assets-62.48% Debt Debt-to-Equity RatioN/A Current Ratio7.47 Quick Ratio7.20 Sales & Book Value Annual Sales$82.71 million Price / Sales4.26 Cash FlowN/A Price / Cash FlowN/A Book Value($2.78) per share Price / Book-5.40Miscellaneous Outstanding Shares23,450,000Free Float20,844,000Market Cap$351.98 million OptionableOptionable Beta1.12 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMs. Elizabeth A. Barrett (Age 62)President, CEO & Director Comp: $1.34MMr. Jason Drew Smith (Age 52)General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $864.19kDr. Mark P. Schoenberg M.D. (Age 66)Chief Medical Officer Comp: $639.83kMr. Dong Kim (Age 46)Chief Financial Officer Comp: $546.68kVincent I. PerroneSenior Director of Investor RelationsMr. Bryon WornsonExecutive Vice President of Talent, Advocacy & CommunicationsDr. Marina KonortyExecutive Vice President of Research & Development and Technical OperationsMr. Jeffrey Bova M.B.A.Chief Commercial OfficerMr. James Ottinger R.ph.Executive Vice President of Regulatory Affairs & QualityDr. Polly A. Murphy D.V.M. (Age 59)M.B.A., Ph.D., Chief Business Officer More ExecutivesKey CompetitorsSpectrum PharmaceuticalsNASDAQ:SPPIAkebia TherapeuticsNASDAQ:AKBAPuma BiotechnologyNASDAQ:PBYIRAPT TherapeuticsNASDAQ:RAPTWave Life SciencesNASDAQ:WVEView All CompetitorsInsiders & InstitutionsMark SchoenbergSold 5,153 sharesTotal: $67,401.24 ($13.08/share)Opaleye Management Inc.Sold 50,000 shares on 5/29/2024Ownership: 1.151%Tidal Investments LLCBought 28,320 shares on 5/17/2024Ownership: 0.121%California State Teachers Retirement SystemSold 1,689 shares on 5/16/2024Ownership: 0.012%Price T Rowe Associates Inc. MDBought 267,143 shares on 5/15/2024Ownership: 1.139%View All Insider TransactionsView All Institutional Transactions URGN Stock Analysis - Frequently Asked Questions Should I buy or sell UroGen Pharma stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" URGN shares. View URGN analyst ratings or view top-rated stocks. What is UroGen Pharma's stock price target for 2024? 3 Wall Street research analysts have issued twelve-month price targets for UroGen Pharma's shares. Their URGN share price targets range from $40.00 to $60.00. On average, they expect the company's share price to reach $51.17 in the next year. This suggests a possible upside of 240.9% from the stock's current price. View analysts price targets for URGN or view top-rated stocks among Wall Street analysts. How have URGN shares performed in 2024? UroGen Pharma's stock was trading at $15.00 on January 1st, 2024. Since then, URGN shares have increased by 0.1% and is now trading at $15.01. View the best growth stocks for 2024 here. When is UroGen Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our URGN earnings forecast. How were UroGen Pharma's earnings last quarter? UroGen Pharma Ltd. (NASDAQ:URGN) issued its quarterly earnings data on Monday, May, 13th. The company reported ($0.97) EPS for the quarter, missing analysts' consensus estimates of ($0.93) by $0.04. The firm earned $18.78 million during the quarter, compared to analysts' expectations of $20.73 million. What ETFs hold UroGen Pharma's stock? ETFs with the largest weight of UroGen Pharma (NASDAQ:URGN) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL).Amplify BlueStar Israel Technology ETF (ITEQ). What other stocks do shareholders of UroGen Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU). When did UroGen Pharma IPO? UroGen Pharma (URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. How do I buy shares of UroGen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:URGN) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free URGN Stock Alerts